Deals & IPOs

424 Capital Exits Reverba in Sale With Undisclosed Buyer and Terms

424 Capital has exited Reverba through a strategic sale, with the buyer and terms undisclosed, ending a 2021 partnership that broadened its patient-engagement platform.

By Nathan Brooks

3 min read

424 Capital Exits Reverba Investment
424 Capital Exits Reverba InvestmentPexels / pixabay

What's News

  • 424 Capital exited Reverba through a strategic transaction; the buyer and financial terms were not disclosed.
  • 424 Capital first partnered with Reverba, then known as Health Perspectives Group, in 2021.
  • Reverba’s Six Degrees Medical acquisition added medical communications, healthcare professional engagement and an international presence.
  • The investment targeted pharmaceutical and biotechnology companies across the therapy lifecycle.
  • Baird served as Reverba’s exclusive financial adviser; Whiteman Osterman & Hannah provided legal counsel.

By Nathan Brooks

424 Capital said it exited Reverba through a strategic transaction whose buyer and financial terms were not disclosed.

The investment dates to 2021, when 424 Capital partnered with Reverba, then known as Health Perspectives Group. 424 Capital said the investment was intended to transform Reverba’s established patient-engagement services into a broader platform for pharmaceutical and biotechnology companies across the therapy lifecycle.

That starting point matters because 424 Capital did not create the business. It invested in an established patient-engagement operation, with the stated aim of extending that work across more of the therapy lifecycle for pharmaceutical and biotechnology clients.

According to 424 Capital, Reverba invested in leadership, operating infrastructure and its commercial organization during the ownership period. Reverba also acquired Six Degrees Medical, adding medical communications and healthcare professional engagement services. 424 Capital said the acquisition established an international presence and expanded Reverba’s involvement into earlier stages of drug development.

Reverba now helps life sciences organizations incorporate insights from patients and healthcare professionals into therapy development and commercialization. Reverba also said its services are intended to make complex diseases and treatments easier for patients to understand.

424 Capital’s sale announcement identified Baird as Reverba’s exclusive financial adviser. Whiteman Osterman & Hannah provided legal counsel.

Amit Nagdev, Partner at 424 Capital, said:

Reverba represents the type of business we seek to build at 424 — one with a compelling mission and a differentiated market position.

We are incredibly proud of what Cheryl and the entire Reverba team accomplished during our partnership. Together, we strengthened the organization, expanded its capabilities, and built a more strategic partner to some of the world’s leading life sciences companies.

Nagdev’s assessment placed the transaction at the end of a buildout. 424 Capital said it strengthened Reverba, expanded its capabilities and made the company a more strategic partner to some of the world’s leading life sciences companies.

Cheryl Lubbert, CEO of Reverba, said:

424 has been an incredibly supportive partner as we have evolved and expanded Reverba. Their team shared our conviction in the importance of our mission and invested alongside us in the people, capabilities, and infrastructure needed to serve our clients and their patients in more meaningful ways.

We are proud of what we have built together and excited about Reverba’s next chapter.

Lubbert credited 424 Capital with investing alongside Reverba in people, capabilities and infrastructure. She also described the sale as the start of Reverba’s next chapter, without identifying the new owner.

For 424 Capital, the exit concludes a 2021 investment in a company then known as Health Perspectives Group. For Reverba, it follows a period in which the business moved beyond its original patient-engagement base, added capabilities through Six Degrees Medical and built an international presence.

What does the exit change for clients?

For clients, the disclosed change is ownership. The announcement gives no financial terms, names no buyer and describes no operational changes. The only disclosed transition is the change in ownership itself, leaving continuity at the center of the transaction for pharmaceutical and biotechnology clients, healthcare professionals and patients.

Because Reverba’s work reaches from earlier drug development through commercialization, continuity spans several parts of the therapy lifecycle. The release identifies no transition plan or buyer, leaving those questions open for clients.

What Reverba has built under 424 Capital is broader than the patient-engagement business it entered in 2021. The Six Degrees Medical acquisition added medical communications, healthcare professional engagement and an international footprint. Reverba now sits earlier in drug development, using patient and healthcare professional insights through therapy development and commercialization.

Clients face a narrower question than whether the company has changed direction. The release points to an expanded service mix and a transfer of ownership, but details no reorganization. Any assessment of future delivery must wait for the buyer’s plans.

The next test is whether the incoming owner preserves those capabilities and the leadership, operating infrastructure and commercial organization 424 Capital funded. The announcement offers no answer on financial terms or buyer, but it presents the expanded service platform—not the sale itself—as the operating asset Reverba carries forward.

Source: pulse2.com

Share this article:

More from Nathan Brooks

Nathan Brooks

Show full bio

News editor covering regulation, policy and their impact on entrepreneurship, startups and venture funding at Business Bearings.

2,611 articles

Related articles

« Previous article